Easyflusan 30mg (Oseltamivir Phosphate)

Adult dose

Influenza A and influenza B virus infections: Begin treatment on the first or second day after the onset of influenza symptoms. This medicine may be taken with or without food; tolerability may improve in some patients when it is taken with food. Adults and adolescents 13 years of age and older: Administer 75 mg of oseltamivir orally twice daily for 5 days. Adults and adolescents 13 years of age and older who have difficulty swallowing capsules should use this medicine for dosing. Patients with renal impairment: No dosage adjustment is required for patients with creatinine clearance of 60 mL/min or more. For patients with creatinine clearance of 30 ~ 60 mL/min, a reduced dose of 30 mg twice daily for 5 days is recommended. For patients with creatinine clearance of 10 ~ 30 mL/min, a reduced dose of 30 mg once daily for 5 days is recommended. Patients receiving regular hemodialysis should receive a 30mg dose of this medicine after each dialysis session to maintain therapeutic plasma concentrations; treatment should not exceed 5 days. If influenza symptoms develop during the 48 hours between dialysis sessions, the dose may also be administered before the start of dialysis. For peritoneal dialysis, a single 30mg dose of this medicine after dialysis is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. Patients with hepatic impairment: No dosage adjustment is required for treatment in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9). Prevention of influenza A and influenza B virus infections Adults and adolescents 13 years of age and older: For those in close contact with an infected person, administer 75 mg of oseltamivir orally once daily for 10 days. Begin administration within 2 days of contact with the infected person. The recommended dose for prevention during an influenza epidemic is 75 mg once daily. The safety and efficacy of this medicine have been demonstrated for up to 6 weeks. The preventive effect continues while this medicine is being taken. Patients with renal impairment: No dosage adjustment is required for patients with creatinine clearance of 60 mL/min or more. For patients with creatinine clearance of 30 ～ 60 mL/min, a reduced dose of 30 mg once daily is recommended. For patients with creatinine clearance of 10 ～ 30 mL/min, a reduced dose of 30 mg once daily every other day is recommended. Patients receiving regular hemodialysis should receive a 30mg dose of this medicine after every 2 dialysis sessions to maintain therapeutic plasma concentrations. The initial dose may be administered before the start of dialysis. For peritoneal dialysis, 30mg of this medicine after dialysis once weekly is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. Patients with hepatic impairment: No dosage adjustment is required for prevention in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

Child dose

Treatment of influenza A and influenza B virus infections — Pediatric patients 1 to 12 years of age: Pediatric patients weighing more than 40 kg may take 75mg capsules twice daily or 30mg capsules and 45mg capsules twice daily. Body weight ≤ 15 kg: 30 mg (sachet) twice daily Body weight 15 kg<, ≤ 23 kg: 45 mg (sachet) twice daily Body weight 23 kg<, ≤ 40 kg: 60 mg (two 30mg sachets) twice daily Body weight > 40 kg: 75 mg (sachet) twice daily Pediatric patients aged 2 weeks to less than 1 year: The recommended dose for pediatric patients aged 2 weeks to 12 months is 3mg/kg of this medicine orally twice daily for 5 days. This does not apply to pediatric patients with a postconceptional age of less than 36 weeks. Pediatric patients who have difficulty taking this medicine as a powder should use the suspension. Body weight 3 kg: 9 mg twice daily; suspension (6mg/mL) 1.5mL twice daily Body weight 4 kg: 12 mg twice daily; suspension (6mg/mL) 2.0mL twice daily Body weight 5 kg: 15 mg twice daily; suspension (6mg/mL) 2.5mL twice daily Body weight 6 kg: 18 mg twice daily; suspension (6mg/mL) 3.0mL twice daily Body weight 7 kg: 21 mg twice daily; suspension (6mg/mL) 3.5mL twice daily Body weight 8 kg: 24 mg twice daily; suspension (6mg/mL) 4.0mL twice daily Body weight 9 kg: 27 mg twice daily; suspension (6mg/mL) 4.5mL twice daily Body weight 10 kg: 30 mg twice daily; suspension (6mg/mL) 5.0mL twice daily This table does not include all possible body weights in this patient group. A dose of 3mg/kg of this medicine is recommended for pediatric patients under 1 year of age. Prevention of influenza A and influenza B virus infections — Pediatric patients 1 to 12 years of age: Pediatric patients weighing more than 40 kg may take 75mg capsules once daily or 30mg capsules and 45mg capsules once daily for 10 days. Body weight ≤ 15 kg: 30 mg (sachet) once daily Body weight 15 kg<, ≤ 23 kg: 45 mg (sachet) once daily Body weight 23 kg<, ≤ 40 kg: 60 mg (two 30mg sachets) once daily Body weight > 40 kg: 75 mg (sachet) once daily The safety and efficacy of prevention of influenza A and B virus infections in pediatric patients under 1 year of age have not been evaluated.

This medication cannot replace influenza vaccination and should be used in conjunction with vaccination. Safety and efficacy have not been established for infections other than influenza A and B virus. Children and adolescents taking this medication may experience abnormal behavior or neuropsychiatric symptoms, requiring special attention; caregivers should not leave them alone for 2 days. It should not be taken if allergic to this medication or its components. Patients with decreased kidney function may require dose adjustments, and it is not recommended for patients with end-stage renal failure. Caution should be exercised when administering to high-risk patients such as those with asthma, chronic bronchitis, or immunosuppression. Common side effects include nausea, vomiting, headache, and pain, most of which are temporary. Serious side effects such as shock, anaphylaxis, liver dysfunction, skin rashes, neuropsychiatric symptoms, and hemorrhagic colitis may occur rarely; immediate consultation with a healthcare professional is necessary if such symptoms arise. Pregnant or breastfeeding women should consider the risks and benefits of using this medication carefully, as there is limited safety data for the fetus or newborn. Safety and efficacy have not been established in children under 1 year, so its use is not recommended. Elderly patients should be closely monitored due to age-related decline in physical and multiple disease factors, although dose adjustments are usually not necessary. Reported adverse reactions from overdose are similar to general side effects, and while no specific treatment is available, healthcare personnel should be informed promptly if symptoms arise. This medication should be stored out of reach of children and should not be transferred to other containers. The potential for interactions with other medications is low, but caution may be needed if taken with specific drugs; inform healthcare professionals if any other medications are being taken. The impact on driving or operating machinery is minimal, but influenza itself may impair physical capabilities, so caution is advised. Starting this medication as soon as possible at the onset of symptoms is effective, and if a dose is missed, it should be taken as soon as possible, but if it's within 2 hours of the next scheduled dose, it is better to skip.

• Convulsions
• delirium
• abnormal behavior
• nausea
• vomiting
• headache
• pain
• unstable angina
• anemia
• pseudomembranous colitis

This medication should be stored in a tightly sealed container to avoid contact with light or air, and it should be stored at a temperature between 1 and 30 degrees Celsius for safety. Storing in this manner helps maintain the medication's effectiveness and prevents degradation.

Appearance

White or slightly yellow powder

Package unit

10 packets/box